ArticleJournal of thrombosis and haemostasis : JTH2026
Ribosomal read through as an alternative therapy for patients with hemophilia with nonsense mutations.
Article in Journal of thrombosis and haemostasis : JTH, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comparative evaluation of TRIDs : a strategy to improve treatments.Journal of translational medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundDrug-induced ribosomal read through can rescue nonsense mutations by inserting a replacement amino acid at the premature termination codon. Hemophilia A (HA) is well suited for this therapy as even modest increases in cofactor activity can substantially improve severe bleeding symptoms. Identifying highly efficient, low-toxicity read through compounds and pinpointing responsive mutations are critical steps in advancing this therapy.
objectivesTo compare the effects of different read through compounds and identify nonsense mutations in F8 that respond to read through treatments.
methodsWe used a cell-based model stably expressing B-domain-deleted factor (F)VIII-Gaussia luciferase fusion proteins to evaluate the efficacy of 2,6-diaminopurine (DAP), ELX-02, and G418. Rescue of nonsense mutants was assessed by measuring secreted luciferase activity, as well as FVIII activity and antigen levels. Immunoprecipitation-immunoblotting was used to detect intracellular and secreted FVIII. DAP efficacy was further investigated in vivo using a mouse model expressing nonsense mutant human FVIII delivered via hydrodynamic tail vein injection.
resultsWe tested 26 nonsense mutations, including the most prevalent ones in hemophilia A. All 3 compounds induced varying levels of read through, but DAP showed higher efficacy than ELX-02 and G418 in most mutants. Immunoblotting confirmed the presence of intact fusion proteins in cell lysates and media after DAP and G418 treatments. Nonsense suppression was also confirmed in full-length FVIII. Rescue efficacy was determined by read through efficiency and the effects of replacement amino acids on FVIII secretion and activity. Finally, DAP treatment rescued the p.R355X mutant of human full-length FVIII expressed in mice, yielding detectable levels of antigen in plasma.
conclusionRibosomal read through therapy offers a promising small-molecule treatment option for managing bleeding symptoms in patients with hemophilia A based on individual mutation profiles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.